Research Advisory Council

PCC is advised and counseled by a Research Advisory Council (RAC) that comprises prominent prostate cancer researchers. The role of RAC is to:
  • Synthesize the results of the peer review process and make recommendations for funding to senior PCC staff
  • Receive reports of the evaluation of PCC research programs and provide advice on the development of new programs and the ongoing improvements to existing programs
  • Lead the identification of strategic research areas that could be targeted with specific Requests For Applications
  • Evaluate the PCC peer review processes and recommend necessary enhancements on an ongoing basis
  • Recommend membership of peer review panels
  • Identify potential national and international opportunities for collaboration
  • Provide advice in the development and refinements of scientific and administrative policies
The Council will be composed of established prostate cancer researchers who:
  • Collectively represent expertise in all areas of prostate cancer research
  • Are broadly representative of all major regions in Canada
  • Individually have a strong track record in peer-reviewed research funding and research output

In addition, the Council will include 2 non-scientific members, one of whom must be a prostate cancer patient or survivor. Each will be identified and selected through a formal nomination process.

Current Membership

Shabbir Alibhai, University Hospital Network, Toronto
Sam Aparicio, BC Cancer Agency, Vancouver
Steve Belway, Community Representative, Calgary
Robert Bristow (Scientific Chair), University Hospital Network, Toronto
Michael Brundage, Queens University, Kingston
Kerry Courneya, University of Alberta, Edmonton
Juanita Crook, BC Cancer Agency, Kelowna
Jim Davie, University of Manitoba, Winnipeg
Stuart Edmonds (Co-Chair), Prostate Cancer Canada,
Aaron Fenster, Robarts Research Institute, London
Martin Gleave, Vancouver Prostate Centre, Vancouver
William Nelson, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
John Oliffe, University of British Columbia, Vancouver
Rodney Ouellette, Atlantic Cancer Research Institute, Moncton
Marie-Elise Parent, INRS–Institut Armand-Frappier Research Centre, Laval
Robert Siemens, Queens University, Kingston
John Valliant, McMaster University, Hamilton

As of November 21, 2012


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
New test developed to detect men at high risk of prostate cancer recurrence

Vienna, Austria: A new genetic “signature” to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). More

CanCertainty for All: Cancer’s Not Fair, But Accessing Treatment Should Be

Toronto, ON – March 10, 2014 – There is no disputing a cancer diagnosis is among the worst news a person or their family could receive. More

$1.8 Million awarded to Movember Rising Stars Supporting Innovators in Prostate Cancer Research

Toronto, ON – February 12, 2014 – Prostate Cancer Canada (PCC) is proud to announce the recipients of its 2014 Movember Rising Star awards in prostate cancer research. More

Support for Those Affected by Prostate Cancer

Toronto, ON - January 28, 2014 – We are pleased to announce a partnership between Prostate Cancer Canada and the Canadian Cancer Society in launching the Prostate Cancer Information Service (PCIS), which provides support to anyone affected by prostate cancer. More


Click here for news archive